To evaluate the pharmacokinetics of TMC125 (etravirine) and darunavir (DRV) with low-dose ritonavir (DRV/r).
Design
Open-label, randomized, two-way crossover Phase I trial.
Methods
Thirty-two HIV-negative volunteers were randomized 1:1 to two panels. All received TMC125 100 mg twice daily for 8 days and, after 14 days washout, DRV/r 600/100 mg twice daily for 16 days. During days 9–16, TMC125 100 or 200 mg twice daily was coadministered (Panel I or II, respectively).
Results
Twenty-three volunteers completed the trial. With DRV/r coadministration, mean exposure (area under the plasma concentration-time curve from 0 to 12 h [AUC12h]) to TMC125 given as 100 mg twice daily was decreased by 37%; maximum and minimum plasma concentrations (Cmax and Cmin) were decreased by 32% and 49%, respectively. For TMC125 200 mg twice daily coadministered with DRV/r, AUC12h, Cmax and Cmin of TMC125 were 80%, 81% and 67% greater, respectively, versus TMC125 100mg twice daily alone. DRV pharmacokinetics were unchanged except a 15% increase in AUC12h when given with TMC125 200 mg twice daily.
Conclusions
No clinically relevant changes in DRV pharmacokinetics were observed when combined with TMC125; therefore DRV dose adjustment is not required. Coadministration of TMC125 100 mg twice daily with DRV/r decreased TMC125 exposure by 37%. The increase of TMC125 exposure by 80% when given as 200 mg twice daily reflects the higher dose and the interaction with DRV/r. The magnitude of this interaction is comparable to TMC125 interactions with other boosted PIs observed in Phase IIb trials in HIV-1-infected patients. As these trials demonstrated TMC125 efficacy, no dose adjustment of TMC125 is needed when combined with DRV/r.
References
1.
HammerS.M., SaagM.S., SchechterM.Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.JAMA2006; 296: 827–843.
2.
Panel on Antiretroviral Guidelines for Adult and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services [updated 2006 October 10; cited 2007 July 11]. Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
3.
De MeyerS., AzijnH., SurlerauxD.TMC114/r, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.Antimicrob Agents Chemother2005; 49: 2314–2321.
4.
KatlamaC., EspositoR., GatellJ.M.Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.AIDS2007; 21: 395–402.
5.
HaubrichR., BergerD., ChiliadeP.Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.AIDS2007; 21: F11–F18.
6.
ClotetB., BellosN., MolinaJ.M.; POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.Lancet2007; 369: 1169–1178.
7.
MolinaJ.M., CohenC., KatlamaC.; on Behalf of the TMC 114-C208 and -C215 Study Groups. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.J Acquir Immune Defic Syndr2007. In press.
8.
AndriesK., AzijnH., ThielemansT.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Antimicrob Agents Chemother2004; 48: 4680–4686.
9.
VingerhoetsJ., AzijnH., FransenE.TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.J Virol2005; 79: 12773–12782.
10.
GazzardB.G., PozniakA.L., RosenbaumW.An open-label assessment of TMC125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.AIDS2003; 17: F49–F54.
11.
GruzdevB., RakhmanovaA., DoubovskayaE.A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral-naive, HIV-1 infected subjects.AIDS2003; 17: 2487–2494.
12.
The TMC125-C223 Writing Group.Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.AIDS2007; 21: F1–F10.
13.
CohenC., SteinhartC.R., WardD.J.Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223.16th International AIDS Conference. 13–18 August 2006, Toronto, Canada. Abstract TUPE0061.
14.
Prezista™ (darunavir). Prescribing information.2006. Tibotec Inc.Yardley, PA, USA.
15.
SekarV., KestensD., Spinosa-GuzmanS.The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.J Clin Pharmacol2007; 47: 479–484.
16.
SekarV., Spinosa-GuzmanS., LefebvreE., HoetelmansR.Clinical pharmacology of TMC114 - a new protease inhibitor.16th International AIDS Conference. 13–18 August 2006, Toronto, Canada. Abstract TUPE0083.
17.
Schöller-GyüreM., RaoofA., MannensG.Mass balance of 14C-labelled TMC125 in healthy volunteers.8th International Workshop of Clinical Pharmacology. 16–18 April 2007, Budapest, Hungary. Abstract 78.
18.
RaoofA., MannensG., MamidiR.In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers.AAPS Annual Meeting and Exposition. October 28–November 2 2006, San Antonio, TX, USA. Abstract M1342.
19.
KakudaT.N., Schöller-GyüreM., WoodfallB.J.TMC125 in combination with other medications: summary of drug-drug interactions.8th International Congress on Drug Therapy in HIV Infection. 12–16 November 2006, Glasgow, UK. Abstract PL5.2.
20.
Schöller-GyüreM., LeemansR., VynckeV.Effect of food on the oral bioavailability of the Phase III formulation of TMC125.7th International Workshop of Clinical Pharmacology. 20–22 April 2006, Lisbon, Portugal. Abstract 80.
21.
BoucheM.P., MichielsenL., PiotM., TimmermanP.Swift and simultaneous determination of darunavir (TMC114) and ritonavir in human plasma using LC-MS/MS.17th International Mass Spectrometry Conference. 27 August-1 September 2006, Prague, Czech Republic. Abstract TuP-042.
22.
Schöller-GyüreM., DebroyeC., WoodfallB.Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate.46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17–20 September 2006, San Francisco, CA, USA. Abstract A-371.
23.
KakudaT.N., Schöller-GyüreM., PeetersM.Pharmacokinetics (PK) and pharmacodynamics (PD) of TMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resistance: TMC125-C223.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA.
24.
BoffitoM., WinstonA., JacksonA.Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high level viral resistance.AIDS2007; 21: 1449–1455.
25.
MontanerJ., HarrisM., KakudaT.Combination of TMC114/r and TMC125 in patients with multidrug resistant HIV.16th International AIDS Conference. 13–18 August 2006, Toronto, Canada. Abstract THPE0136.
26.
HsuA., GrannemanG.R., BertzR.J.Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents.Clin Pharmacokinet1998; 35: 275–291.
27.
FaucetteS.R., WangH., HamiltonG.A.Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.Drug Metab Dispos2004; 32: 348–358.
28.
WilliamsL.A., O'DeaR., WeinbergM.High incidence of rash associated with amprenavir (APV) during a pharmacokinetic (PK) interaction trial in HIV-negative, healthy volunteers.13th International AIDS Conference. 9–14 July 2000, Durban, South Africa. Abstract WePeB4252.
29.
MontanerJ., DomingoP., JunodP.Safety and tolerability of TMC125 in 3-class-experienced HIV-infected patients: 24-week primary analysis of trial TMC125–C203.European AIDS Conference. 17–20 November 2005, Dublin, Ireland. Abstract LBPS3/7B.
